Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03647358 · ClinicalTrials.gov registry record · Phase 1
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
A Phase 1 study of Thyroid Carcinoma and Metastatic Thyroid Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03647358: Recruiting Phase 1 study of Thyroid Carcinoma and Metastatic Thyroid Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03647358 is a Phase 1 study of Thyroid Carcinoma and Metastatic Thyroid Carcinoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03647358, a Phase 1 study of Thyroid Carcinoma and Metastatic Thyroid Carcinoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new test determines sufficient radioiodine uptake in the cancer, treatment will continue as usual. However, if the new test shows only low radioiodine uptake, a decision may be made that the benefit from radioiodine therapy is insufficient and that another form of therapy is preferred.
Primary Outcome
This will be accomplished using a logistic regression model using lesion as the unit of analysis and adjusting for possible correlation between lesions on the same patient using a random effect at the patient level. by RECIST 1.1
Conditions Studied
Interventions
- DEVICE PET/CT Scan
- DRUG Iodine-124
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-08-21 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What NCT03647358 shows while recruiting
NCT03647358 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 2 conditions, with Thyroid Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which PET/CT Scan is the first listed.
NCT03647358 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03647358 about?
NCT03647358 is a clinical study titled "Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma". The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new test determines suffici...
What is the current status of trial NCT03647358?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2018-08-21. Estimated completion is 2027-08.
What conditions does trial NCT03647358 study?
This clinical trial studies the following conditions: Thyroid Carcinoma, Metastatic Thyroid Carcinoma.
What interventions are being tested in trial NCT03647358?
The interventions under investigation include: PET/CT Scan (DEVICE), Iodine-124 (DRUG).
Who is sponsoring clinical trial NCT03647358?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03647358 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03647358's enrollment target sits among peer trials
60 832nd of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI